Sensorion

147 articles about Sensorion

• Sensorion : A Chardan Top Pick for 2021

  2/17/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the US healthcare investment bank Chardan decision to make Sensorion one of its top picks for 2021, calling the company “2021’s hidden gem in gene therapy”.

• Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

  2/15/2021

  Key new findings by the Institut Pasteur concerning the gene target GJB2, enables Sensorion to potentially address important hearing loss segments in adults and children

• Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation

  1/19/2021

  Sensorion announces preclinical data showing that the combination of its SENS-401 molecule with cochlear implants reduced loss of residual hearing at a frequency located beyond the electrode array.

• Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation

  1/7/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the investment banks Jefferies and Kempen have initiated analyst coverage of Sensorion.

• Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

  1/5/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat CIO in H2 2021.

• Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss

  12/15/2020

  Sensorion announces that Sonova Holding AG, a leading provider of hearing solutions, will acquire a 3.7% ownership stake in Sensorion by way of subscription to a reserved share capital increase for total gross proceeds of €5 million.

• Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020

  11/20/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it will host a key opinion leader call on genetic hearing loss in children on Wednesday, December 2, 2020 at 8:00am Eastern Time.

• Sensorion Announces Attendance and a Presentation at Upcoming Conferences - Nov 03, 2020

  11/3/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its attendance and presentation at upcoming conferences.

• 

  BioSpace Global Roundup, Oct. 29

  10/29/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement

  10/27/2020

  Sensorion and Novasep announce the signature of an agreement for the manufacturing of adeno-associated virus vectors.

• Sensorion Obtains €3 Million Loans, Including €2 Million Guaranteed by the French Government (PGE) and €1 Million as RDI Loan Through Bpifrance

  10/15/2020

  Loan reinforces the financial foundation of the company and extends Sensorion cash runway until early Q4 2022

• Sensorion Announces Attendance and Presentations at Upcoming Conferences - Oct 01, 2020

  10/1/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its attendance and presentations at a number of upcoming conferences.

• Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA

  8/14/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces presentations at upcoming congresses.

• Sensorion appoints five renowned experts to its Scientific Advisory Board

  7/29/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of five renowned experts to its Scientific Advisory Board.

• Sensorion Will Present at the Bioprocessing Summit Europe Virtual Conference on July 21-23, 2020

  7/20/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that Christine Le Bec, Head of CMC Gene Therapy, will be giving a talk and chairing part of the Bioprocessing Summit Europe conference, to be held virtually July 21-23, 2020.

• Sensorion Hosting Key Opinion Leader Call with Dr. Michael Hoffer on Sudden Sensorineural Hearing Loss and SENS-401 as a Potential Treatment Option on July 23, 2020

  7/16/2020

  Sensorion announces it will host a key opinion leader call on Sudden Sensorineural Hearing Loss and SENS-401 as a potential treatment option on Thursday, July 23, 2020 at 12:30pm Eastern Time.

• 

  BioSpace Movers & Shakers, July 10

  7/10/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board

  7/6/2020

  Sensorion a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Edwin Moses, former Chief Executive Officer of Ablynx, as Chairman of its Board of Directors.

• Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation

  6/17/2020

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the healthcare investment bank Chardan has initiated analyst coverage of Sensorion.

• 

  BioSpace Global Roundup, June 11

  6/11/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.